Telomir Pharmaceuticals, Net Worth
Telomir Pharmaceuticals, Net Worth Breakdown | TELO |
Telomir Pharmaceuticals, Net Worth Analysis
Telomir Pharmaceuticals,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Telomir Pharmaceuticals,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Telomir Pharmaceuticals,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Telomir Pharmaceuticals,'s net worth analysis. One common approach is to calculate Telomir Pharmaceuticals,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Telomir Pharmaceuticals,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Telomir Pharmaceuticals,'s net worth. This approach calculates the present value of Telomir Pharmaceuticals,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Telomir Pharmaceuticals,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Telomir Pharmaceuticals,'s net worth. This involves comparing Telomir Pharmaceuticals,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Telomir Pharmaceuticals,'s net worth relative to its peers.
To determine if Telomir Pharmaceuticals, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Telomir Pharmaceuticals,'s net worth research are outlined below:
| Telomir Pharmaceuticals, had very high historical volatility over the last 90 days | |
| Net Loss for the year was (16.53 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Telomir Pharmaceuticals, generates negative cash flow from operations | |
| Telomir Pharmaceuticals, has a poor financial position based on the latest SEC disclosures | |
| About 34.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Telomir Pharmaceuticals Announces Breakthrough Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines |
Follow Telomir Pharmaceuticals,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 123.52 M.Market Cap |
|
Project Telomir Pharmaceuticals,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (12.49) | (13.11) | |
| Return On Capital Employed | (1.32) | (1.25) | |
| Return On Assets | (12.49) | (13.11) | |
| Return On Equity | (25.71) | (24.42) |
When accessing Telomir Pharmaceuticals,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Telomir Pharmaceuticals,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Telomir Pharmaceuticals,'s profitability and make more informed investment decisions.
Evaluate Telomir Pharmaceuticals,'s management efficiency
Telomir Pharmaceuticals, has return on total asset (ROA) of (2.5096) % which means that it has lost $2.5096 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1018) %, meaning that it created substantial loss on money invested by shareholders. Telomir Pharmaceuticals,'s management efficiency ratios could be used to measure how well Telomir Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of February 2025, Return On Tangible Assets is likely to drop to -13.11. In addition to that, Return On Capital Employed is likely to grow to -1.25. At this time, Telomir Pharmaceuticals,'s Total Assets are very stable compared to the past year. As of the 27th of February 2025, Total Current Assets is likely to grow to about 1.6 M, while Non Current Assets Total are likely to drop 0.00.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.02 | 0.02 | |
| Tangible Book Value Per Share | 0.02 | 0.02 | |
| Enterprise Value Over EBITDA | (16.33) | (17.15) | |
| Price Book Value Ratio | 189.26 | 198.72 | |
| Enterprise Value Multiple | (16.33) | (17.15) | |
| Price Fair Value | 189.26 | 198.72 | |
| Enterprise Value | 108.4 M | 96.3 M |
The decision-making processes within Telomir Pharmaceuticals, are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Telomir Pharmaceuticals, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Telomir Pharmaceuticals,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Telomir Pharmaceuticals, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yanez Michelle over six months ago Acquisition by Yanez Michelle of 200000 shares of Telomir Pharmaceuticals, at 5.02 subject to Rule 16b-3 | ||
Bay Shore Trust over a year ago Purchase by Bay Shore Trust of 49000 shares of Telomir Pharmaceuticals | ||
Bay Shore Trust over a year ago Telomir Pharmaceuticals exotic insider transaction detected |
Telomir Pharmaceuticals, Corporate Filings
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F5 | 4th of February 2025 The annual filing required by the Securities and Exchange Commission (SEC) from company insiders or beneficial owners | ViewVerify |
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Telomir Pharmaceuticals, Earnings per Share Projection vs Actual
Telomir Pharmaceuticals, Corporate Executives
Elected by the shareholders, the Telomir Pharmaceuticals,'s board of directors comprises two types of representatives: Telomir Pharmaceuticals, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telomir. The board's role is to monitor Telomir Pharmaceuticals,'s management team and ensure that shareholders' interests are well served. Telomir Pharmaceuticals,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telomir Pharmaceuticals,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD ODonnell | Chief Cofounder | Profile | |
| Nathen CPA | Treasurer, CFO | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telomir Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.